Project: Two highly potent, unique drug candidates targeting huge medical needs in wound healing.
| Acronym | New PDEI drugs in wounds. (Reference Number: 10192) |
| Duration | 01/06/2016 - 01/06/2018 |
| Project Topic | The ultimate goal is to unveil the potential of Topadur owned topical dual mode of action drugs for abnormal cutaneous wound healing addressing huge medical needs: TOP-N53 (NO releasing PDE5 inhibitor) to accelerate chronic wound closure as in diabetic foot ulcer. TOP-N44 (PDE4 inhibitor prodrug/Corticosteroid) to prevent excessive fibrotic scarring as in hypertrophic scars from burns or keloid. Studies herein are on the critical path to validate efficacy in disease related preclinical models. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 4 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 23199 | Topadur Pharma AG | Coordinator | Switzerland |
| 23200 | University of Luebeck | Partner | Germany |
| 23201 | ETH Zurich | Partner | Switzerland |